Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer.

Autor:	Furman C; H3 Biomedicine Inc., Cambridge, Massachusetts., Puyang X; H3 Biomedicine Inc., Cambridge, Massachusetts., Zhang Z; H3 Biomedicine Inc., Cambridge, Massachusetts., Wu ZJ; H3 Biomedicine Inc., Cambridge, Massachusetts., Banka D; H3 Biomedicine Inc., Cambridge, Massachusetts., Aithal KB; Aurigene Discovery Technologies Ltd, Bangalore, Karnataka, India., Albacker LA; Foundation Medicine Inc., Cambridge, Massachuetts., Hao MH; H3 Biomedicine Inc., Cambridge, Massachusetts., Irwin S; H3 Biomedicine Inc., Cambridge, Massachusetts., Kim A; H3 Biomedicine Inc., Cambridge, Massachusetts., Montesion M; Foundation Medicine Inc., Cambridge, Massachuetts., Moriarty AD; START, Preclinical Research, San Antonio, Texas., Murugesan K; Foundation Medicine Inc., Cambridge, Massachuetts., Nguyen TV; H3 Biomedicine Inc., Cambridge, Massachusetts., Rimkunas V; H3 Biomedicine Inc., Cambridge, Massachusetts., Sahmoud T; H3 Biomedicine Inc., Cambridge, Massachusetts., Wick MJ; START, Preclinical Research, San Antonio, Texas., Yao S; H3 Biomedicine Inc., Cambridge, Massachusetts., Zhang X; H3 Biomedicine Inc., Cambridge, Massachusetts., Zeng H; H3 Biomedicine Inc., Cambridge, Massachusetts., Vaillancourt FH; H3 Biomedicine Inc., Cambridge, Massachusetts., Bolduc DM; H3 Biomedicine Inc., Cambridge, Massachusetts., Larsen N; H3 Biomedicine Inc., Cambridge, Massachusetts., Zheng GZ; H3 Biomedicine Inc., Cambridge, Massachusetts., Prajapati S; H3 Biomedicine Inc., Cambridge, Massachusetts., Zhu P; H3 Biomedicine Inc., Cambridge, Massachusetts., Korpal M; H3 Biomedicine Inc., Cambridge, Massachusetts.
Jazyk:	angličtina
Zdroj:	Molecular cancer therapeutics [Mol Cancer Ther] 2022 Jun 01; Vol. 21 (6), pp. 890-902.
DOI:	10.1158/1535-7163.MCT-21-0378
Abstrakt:	Nearly 30% of patients with relapsed breast cancer present activating mutations in estrogen receptor alpha (ERα) that confer partial resistance to existing endocrine-based therapies. We previously reported the development of H3B-5942, a covalent ERα antagonist that engages cysteine-530 (C530) to achieve potency against both wild-type (ERαWT) and mutant ERα (ERαMUT). Anticipating that the emergence of C530 mutations could promote resistance to H3B-5942, we applied structure-based drug design to improve the potency of the core scaffold to further enhance the antagonistic activity in addition to covalent engagement. This effort led to the development of the clinical candidate H3B-6545, a covalent antagonist that is potent against both  ERαWT/MUT, and maintains potency even in the context of ERα C530 mutations. H3B-6545 demonstrates significant activity and superiority over standard-of-care fulvestrant across a panel of ERαWT and ERαMUT palbociclib sensitive and resistant models. In summary, the compelling preclinical activity of H3B-6545 supports its further development for the potential treatment of endocrine therapy-resistant ERα+ breast cancer harboring wild-type or mutant ESR1, as demonstrated by the ongoing clinical trials (NCT03250676, NCT04568902, NCT04288089). Summary: H3B-6545 is an ERα covalent antagonist that exhibits encouraging preclinical activity against CDK4/6i naïve and resistant ERαWT and ERαMUT tumors. (©2022 The Authors; Published by the American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu